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Icariin, a ﬂavonoid isolated from Epimedii herba, stimulated phosphorylation of endothelial nitric
oxide synthase (eNOS) at Ser1177, Akt (Ser473) and ERK1/2 (Thr202/Tyr204). The icariin-induced
eNOS phosphorylation was abolished by an androgen receptor (AR) antagonist, nilutamide in
human umbilical vein endothelial cells (HUVECs). Furthermore, it was also reduced in the cells
transfected with small interfering RNA in which the expression of AR was broken down. The ica-
riin-induced eNOS phosphorylation was inhibited by wortmannin, a phosphatidylinositol 3-kinase
(PI3K) inhibitor and partially attenuated by PD98059, an upstream inhibitor for ERK1/2. These data
suggest that icariin stimulates release of NO by AR-dependent activation of eNOS in HUVECs. PI3K/
Akt and MAPK-ERK kinase (MEK)/ERK1/2 pathways were involved in the phosphorylation of eNOS by
icariin.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction It has been reported that icariin stimulates the synthesis of ni-Epimedium, a traditional Chinese herb, is widely used for treat-
ing various diseases including coronary heart disease, impotence
and osteoporosis [1–3].
The active constituents of the herb are ﬂavonoids, mainly icariin
(C33H40O15; molecular weight: 676.662 g/mol) (Fig. 1) which
signiﬁcantly dilates coronary arteries, attenuates myocardial dys-
function, improve the sexual function, stimulates osteoblast prolif-
eration, and enhances immune function [4–6]. Recently, icariin has
been demonstrated to act as a phosphodiesterase-5 inhibitor [7,8]
and to enhance the production of bioactive nitric oxide (NO) [9], as
well as mimicking the effects of testosterone [10]. Icariin has
therapeutic potential in the management of hypoandrogenism
and coronary artery disease.chemical Societies. Published by E
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-1, Hongo, Bunkyo-ku, Tokyotric oxide synthase (NOS) and increased NO production, the events
were correlated with activation of the PI3K/Akt and MAPK-ERK ki-
nase (MEK)/ERK1/2 pathways [11]. These precise mechanisms of
actions on vascular endothelial cells have not been fully under-
stood. NO released from endothelial cell via the endothelial nitric
oxide synthase (eNOS) is a pivotal vasoprotective molecule. It not
only improves vascular relaxation, but also inhibits of platelet
aggregation, leukocyte adhesion, smooth muscle cell proliferation,
and expression of genes involved in atherosclerosis [12].
Androgen receptor (AR) is a member of the nuclear receptor
superfamily, which exerts its effects by modifying gene expression
[13]. We have previously reported that AR is involved in eNOS acti-
vation induced by ginsenoside-Rb1, a steroid hormone-like herb,
through phosphatidylinositol 3-kinase (PI3K)/Akt signaling [14].
In this study, we investigated the effect of icariin on eNOS activa-
tion and NO production and further explored the role of AR and
its signaling pathway in human umbilical vein endothelial cells
(HUVECs).
2. Materials and methods
2.1. Chemicals and reagents
Icariin and actinomycin D were purchased from Wako (Wako
Pure Chemical Industries Ltd., Osaka, Japan). Nilutamide, N-nitro-
L-arginine methyl ester (L-NAME) (hydrochloride), Hanks’ balancedlsevier B.V. All rights reserved.
Fig. 1. Chemical structures of icariin.
H. Koizumi et al. / FEBS Letters 584 (2010) 2440–2444 2441salt solution (HBSS) were purchased from Sigma (St. Louis, MO,
USA). ICI 182780 was from Zeneca Pharmaceuticals (Macdesﬁeld,
UK). PD98059 and wortmannin were from Calbiochem (EDM
Biosciences Inc., La Jolla, CA, USA). Small interfering RNA duplex
oligonucleotides were purchased from Santa Cruz (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). Nitric Oxide Synthase
Assay Kit was obtained from Dojin (Dojindo Laboratories, Kuma-
moto, Japan). Antibodies against phosphorylated eNOS (p-eNOS)
(Ser1177) and eNOS/NOS type III were purchased form BD Trans-
duction Laboratories (BD Biosciences, Franklin Lakes, NJ, USA). All
other antibodies were form Cell Signaling Technology (Beverly,
MA, USA). LumiGLO Reserve Chemiluminescent Substrate Kit was
from KPL (Gaithersburg, MD, USA). Endothelial cell base medium
(EBM-2) was from Clonetics (Walkersville, MD, USA). HUVECs were
from Cambrex (Cambrex BioScienceWalkersville Inc., Walkersville,
MD, USA). Fetal bovine serum (FBS) was from CCT (Sanko Junyaku
Co. Ltd., Tokyo, Japan), FBS charcoal stripped was from MultiSer
(ThermoTrace Ltd., Melbourne, Australia).
2.2. Cell culture
HUVECs were cultured in a 37 C humidiﬁed atmosphere of 95%
air/5% CO2 in endothelial cell grows medium 2 (EGM-2) supple-
mented with 10% FBS. The EGM-2 medium consisted of 0.1% EGF,
0.04% hydrocortisone, 0.4% hFGF-B, 0.1% VEGF, 0.1% R3-IGF-1,
0.1% ascorbic acid, 0.1% GA-1000 and 0.1% heparin. Experiments
were performed with cells from passages 5 to 9. For all experi-
ments, HUVECs were plated at a concentration of 1  104 mL1
and grown to conﬂuence. Then the cells were incubated in phenol
red- and growth factor cocktail-free EBM-2 medium supplemented
with 1% dextran-coated charcoal- (DCC) stripped FBS (condition
medium) for 6 h to diminish steroids and to obtain growth arrest.
In some inhibitory experiments, the inhibitors were added to
cells 60 min before the stimulators. Dimethyl sulfoxide (DMSO)
was used as a solvent for icariin, PD98059, wortmannin, L-NAME,
and nilutamide present at equal concentrations (0.001%) in all
groups, including the control.
2.3. Western blot analysis
After treatment with reagents, conﬂuent monolayers of cells
were washed two times in ice-cold phosphate-buffered saline
and lysed with buffer containing 20 mmol/L Tris–HCl (pH 7.5),
150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton-X,
2.5 mmol/L sodium pyrophosphate, 1 mmol/L b-glycerophosphate,
1 mmol/L Na3VO4, 1 lg/mL leupeptin and 1 mmol/L PMSF. For
immunoblot analysis, total cell lysate was subjected to SDS–PAGE,
and proteins were transferred to polyvinylidene diﬂuoride (PVDF)
membrane. The antibodies used in this study were anti-p-ERK1/2
(Thr202/Tyr204), anti-ERK1/2, anti-p-Akt (Ser473), anti-Akt, anti-p-eNOS (ser1177) and anti-eNOS. Antibodies were detected by
means of a horseradish peroxidase-linked secondary antibody
and immunoreactive bands were visualized using LumiGLO Re-
serve Chemiluminescent Substrate Kit.
2.4. Small interfering RNA (siRNA) transfections
siRNA, sometimes known as short interfering RNA or silencing
RNA, is a class of double-stranded RNA molecules that play a vari-
ety of roles in biology. siRNA transfections were performed as de-
scribed previously in detail [15]. siRNA duplexes inhibited
androgen receptor (AR-siRNA) and estrogen receptor alpha (ERa-
siRNA) were used for directed knock down gene expression sepa-
rately. HUVECs were plated in 60 mm collagen-coated culture
dishes and grown in non-antimicrobial culture medium. After
40–50% cell conﬂuent, cells were transfected with 5 nmol/L AR-siR-
NA or 10 nmol/L ERa-siRNA exhibited in experiments separately
using HiperFect transfection reagent in 1 mL transfection medium.
Two hours after, added 3 mL culture medium to each dish for an-
other 24 h. HUVECs were washed with HBSS and starved for 6 h.
Transfection effect was evaluated by Western blot analysis using
antibodies against AR and ERa. Non-silencing random siRNA was
used as a negative control.
2.5. Measurement of intracellular production of NO
Nitrite production in culture mediumwas identiﬁed by measur-
ing the NO production using the ﬂuorometric 2,3-diaminonaphtha-
lene kit by the ﬂuorescence detection method [16]. This method is
based on the reaction of 2,3-diaminonaphthalene (DAN) with ni-
trite under acidic conditions to form 1-(H)-naphthotriazole, a ﬂuo-
rescent product. Brieﬂy, conﬂuent cells in six-well dish were
serum-starved for 6 h. Cells were then treated with icariin or other
stimulators. In some inhibitory experiments, the inhibitors were
administered 60 min before treatment with icariin. In a black 96-
well microtiter plate (PerkinElmer Inc., Boston, MA, USA), 10 lL
of freshly prepared ﬂuorescence reagent (DAN) solution were
added to 100 lL of each sample. After mixing well, the samples
were incubated for 15 min at room temperature and the reaction
was then terminated by the addition of 40 lL of stop solution.
Fluorescence was read with excitation and emission wavelengths
of kex 365 nm and kem 450 nm using a ﬂuorescence microtiter plate
reader (Wallac 1420 ARVO MX/Light, PerkinElmer Japan Co. Ltd.,
Yokohama, Japan). For each NO measurement, the experiments
were repeated three times.
2.6. Statistical analysis
All data are means ± S.E.M. Statistical comparisons between
groups were performed by one-way ANOVA followed by Student’s
t-test. Differences at P < 0.05 were considered statistically
signiﬁcant.3. Results
3.1. Icariin stimulates rapid NO production and eNOS activation in
HUVECs
We examined NO production in HUVECs treated with icariin
(0.1 lmol/L) in the presence or absence of the NOS inhibitor L-
NAME (0.5 mmol/L) with acetylcholine (1 lmol/L), positive con-
trol. NO production was detected using the ﬂuorometric 2,3-diami-
nonaphthalene kit by the ﬂuorometric method to determine
whether the NO increase was attributable to NOS derived de novo
synthesis.
Fig. 2. Effects of icariin on NO production and eNOS phosphorylation in HUVECs. (A) HUVECs were starved for 6 h and then treated with icariin (0.1 lmol/L) or positive
control, acetylcholine (1 lmol/L). Nitric oxide synthase inhibitor, L-NAME (0.5 mmol/L) was administered 60 min before treatment with icariin. Nitrite production in culture
medium was assessed by measuring the NO production using the ﬂuorometric method as described in Section 2. Data were converted to percentage of control (0.162 lmol/L
NO/60 min/1  104 cells) and expressed as means ± S.E.M. of three independent experiments. **P < 0.01 versus icariin alone. (B and C) Phosphorylation of eNOS in HUVECs.
Starved HUVECs were treated with the vehicle (0.001% DMSO) or icariin (0.1 lmol/L) for indicated times (B) or with various concentrations of icariin for 60 min (C). Western
blot analysis performed to detect p-eNOS (Ser1177) and total eNOS. The experiments were repeated three times in triplicates, with equal result.
Fig. 3. Effects of nilutamide, an antagonist of androgen receptor, and AR-siRNA on eNOS phosphorylation and NO production. (A) HUVECs were starved 6 h and then treated
with or without icariin (0.1 lmol/L) for 60 min. Some groups of cells were pre-treated with androgen receptor antagonist nilutamide (10 lmol/L) or estrogen receptor
antagonist ICI 182780 (10 lmol/L) for 1 h. Cell lysates were then subjected to immunoblotting as described in Section 2. The experiments were repeated three times in
triplicates, with equal results. (B) HUVECs were starved for 6 h and then treated with icariin (0.1 lmol/L). Nilutamide or ICI 182780 was administered 60 min before
treatment with icariin. Nitrite production in culture medium was assessed by measuring the NO production using the ﬂuorometric method as described in Section 2. The data
represent the means ± S.E.M. of three independent experiments. **P < 0.01 versus icariin alone. (C) HUVECs were transfected with 5 nmol/L AR-siRNA or 10 nmol/L ERa-siRNA
exhibited in experiments separately using HiperFect transfection reagent in 1 mL transfection medium. Cells were starved for 6 h. Transfection effect was evaluated by
Western blot analysis using antibodies against AR and ERa. Non-silencing random siRNA was used as a negative control. The experiments were repeated three times in
triplicates, with equal results.
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trol cells, and this increase was signiﬁcantly inhibited by the addi-
tion of NOS inhibitor L-NAME (Fig. 2A). The results indicated that
the prominent increase in NO production after icariin treatment
was mediated by an increase in NOS activity.
To conﬁrm whether the activation of eNOS was involved in the
NO increase by icariin, eNOS phosphorylation at Ser1177 was
tested by Western blot. As shown in Fig. 2B and C, icariin induced
rapid eNOS phosphorylation after 5 min of incubation, maximal
eNOS phosphorylation by icariin was attained at 60 min. The rela-
tive magnitude of eNOS phosphorylation falls subsequently but is
still signiﬁcantly greater than control after 120 min of icariin incu-
bation (Fig. 2B, upper blots). The acute effect by icariin on eNOS
phosphorylation was concentration-dependent (Fig. 2C, upper
blots). Icariin did not affect eNOS protein expression (Fig. 2B and
C, lower blots).3.2. AR mediates the activation of eNOS by icariin
Increasing evidences show that activation of the steroid hor-
mone receptor such as estrogen receptor (ER) lead to NO produc-
tion and vasodilation within minutes by non-transcriptional
pathways. To see whether steroid hormone receptors were in-
volved in the icariin-induced activation of eNOS to produce
NO, we examined the effects of an AR antagonist, nilutamide
or an ER antagonist, ICI 182780, while icariin has not steroidal
skeleton structure. Representative Western blots obtained using
anti-p-eNOS (Ser1177) antibody and anti-eNOS antibody are
shown in Fig. 3A. The icariin-induced eNOS phosphorylation
(Ser1177) was inhibited by the AR antagonist nilutamide
(10 lmol/L), but not by ICI 182780 (10 lmol/L). NO production
was also markedly diminished by nilutamide but not by ICI
182780 (Fig. 3B).
Fig. 4. Effects of inhibitors for PI3K/Akt or MEK/ERK1/2 on eNOS phosphorylation and NO production. Starved HUVECs were treated with the vehicle (0.001% DMSO) or icariin
(0.1 lmol/L) for indicated times (B) or with various concentrations of icariin for 60 min (A). In some groups, cells were pre-treated with wortmannin (5 lmol/L) or PD98059
(10 lmol/L) for 1 h, then cells were treated with or without icariin (0.1 lmol/L) for 60 min (C). Cell lysates were analyzed byWestern blot as described in Section 2. Anti-p-Akt
(Ser473) antibody and anti-Akt antibody; anti-p-ERK1/2 antibody and anti-ERK1/2 antibody (A and B), anti-p-eNOS (Ser1177) antibody and anti-eNOS antibody (C) were used
for immunoblot analysis. Experiments were repeated three times in triplicates, with equal result. (D) HUVECs were starved for 6 h and then treated with icariin (0.1 lmol/L).
Wortmannin (5 lmol/L) or PD98059 (10 lmol/L) were administered 60 min before treatment with icariin. Nitrite production in culture medium was assessed by measuring
the NO production using the ﬂuorometric method as described in Section 2. The data represent the means ± S.E.M. of three independent experiments. *P < 0.05 and **P < 0.01
versus icariin alone.
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sion of AR. The expected AR was present in control and non-spe-
ciﬁc targeting siRNA cells, whereas, the expression of AR was
signiﬁcantly reduced in those cells transfected with AR-siRNA.
The phosphorylation of eNOS-induced by icariin was signiﬁcantly
reduced by suppressing expression of AR, as compared with that
of control-transfected cells. In contrast, pretreatment with ERa-
siRNA dose not affect phosphorylation of eNOS-induced by icariin
(Fig. 3C).
To examine whether the icariin-induced increase in eNOS phos-
phorylation is due to a genomic or non-genomic action, the tran-
scription inhibitor, actinomycin D, was added to HUVECs prior to
treatment with icariin. The activation of eNOS was not inhibited
by actinomycin D (data not shown). These results suggest that
the eNOS activity of icariin is exerted through a non-genomic
action.
3.3. PI3K/Akt and MEK/ERK1/2 pathways are involved in eNOS
phosphorylation and NO production induced by icariin
Recent studies have shown that PI3K/Akt and MEK/ERK1/2
pathways are two important signaling cascades mediating eNOS
activation in vascular endothelial cells [17,18]. We examined
whether icariin could activate Akt and ERK1/2. We used phos-
pho-speciﬁc antibodies to evaluate the ability of icariin to stimu-
late phosphorylation of Akt and ERK1/2 in HUVECs.
Icariin increased Akt and ERK1/2 phosphorylation in a concen-
tration-dependent manner (Fig. 4A, upper blots). Akt (Ser473)
phosphorylation was initially observed 5 min after icariin treat-ment and reached the maximum level at 30 min, ERK1/2
(Thr202/Tyr204) phosphorylation was observed 5 min after icariin
treatment and maximal phosphorylation was attained at 15 min
(Fig. 4B, upper blots). The relative magnitude of the icariin re-
sponse falls subsequently but is still signiﬁcantly greater than con-
trol after 120 min of icariin treatment. Icariin did not affect total
Akt and ERK1/2 protein expression (Fig. 4A and B, lower blots).
We next examined the rapid phosphorylation of eNOS at
Ser1177 by icariin either in the presence or absence of PI3K inhib-
itor wortmannin and MEK inhibitor PD98059. As shown in Fig. 4C,
the rapid eNOS phosphorylation was abolished by pretreatment of
cells with wortmannin (5 lmol/L) and partially attenuated by
PD98059 (10 lmol/L). NO production demonstrated by the ﬂuores-
cence detection method using DAN was also inhibited by these
inhibitors (Fig. 4D). These results suggest that acute activation of
eNOS and NO production by icariin were mediated through activa-
tion of PI3K/Akt and ERK1/2.
4. Discussion
We have shown that icariin stimulates prominent release of NO
by AR-dependent activation of eNOS in HUVECs.
Puriﬁed icariin increased NO production in HUVECs compared
with control cells. The increase in NO production was abrogated
by the addition of NOS inhibitor, L-NAME. It is generally well
known that eNOS is tightly regulated not only at the transcrip-
tional level but also by several non-genomic post-transcriptional
mechanisms [19]. The enhanced phosphorylation at Ser1177 has
been known to increased eNOS activity. In our studies, icariin
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icariin treatment. Maximal eNOS phosphorylation by icariin was
attained at 60 min of incubation. In addition, the increase in eNOS
phosphorylation was not inhibited by actinomycin D (data not
shown). Taken together, our data suggested that the effect on NO
production in HUVECs is attributable to rapid phosphorylation of
eNOS at Ser1177 and that the eNOS activation by icariin is exerted
through a non-genomic action.
An interesting ﬁnding is that acute phosphorylation of eNOS by
icariin was abolished by nilutamide, an antagonist for AR or by AR-
siRNA. The effects of icariin on eNOS activity and NO production
were reversed when the cells were pre-treated with AR antagonist
nilutamide, or AR-siRNA. In contrast, the magnitudes of the icariin-
induced phosphorylation of eNOS were unchanged by ER inhibitor,
ICI 182780 or by the ER gene breakdown with ERa-siRNA. These
results suggest that the vascular response induced by icariin is
AR-speciﬁc, and this ﬂavonoid glycoside serves as a novel phytoan-
drogen. While icariin has not steroidal skeleton structure, it exerts
the AR-mediated action on the vascular endothelial cells. The
mechanisms by which icariin interacts with ARs are not known.
However, this study was not designed to address this question,
and therefore future studies will be necessary to investigate the
mechanisms of interaction with ARs of this non-steroidal
ﬂavonoid.
Recent reports have revealed that PI3K/Akt and ERK1/2 path-
ways are crucial regulator in cell proliferation, cell-cycle progres-
sion, and mediator of cellular survival. Both of them also
contribute to enhanced phosphorylation of eNOS at Ser1177 and
production of NO [17,18]. In the present study, icariin also stimu-
lated the phosphorylation of Akt (Ser473) and ERK1/2 (Thr202/
Tyr204) in HUVECs. Icariin-induced eNOS phosphorylation was
prevented by inhibitors for PI3K/Akt or MEK. Taken together, the
results suggest that the activation of PI3K/Akt and MEK/ERK1/2-
mediated pathways is involved in the AR-dependent eNOS phos-
phorylation by icariin in HUVECs.
Our observation that icariin stimulates NO production by
AR-dependent activation of eNOS will be the beginning of the
experimental analyses at molecular levels to elucidate the action
of phytoandrogens for future studies and may provide a clue for
better understanding of the mechanisms by which icariin exerts
its pharmacological activities in a variety of human disorders.
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